Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obseva SA    OBSV   CH0346177709

OBSEVA SA (OBSV)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
10.8(c) 11.16(c) 11.3(c) 10.75(c) 10.03(c) Last
15 287 15 097 25 263 32 352 51 806 Volume
-7.46% +3.33% +1.25% -4.87% -6.70% Change
More quotes
Financials ($)
Sales 2017 0,01 M
EBIT 2017 -68,1 M
Net income 2017 -66,8 M
Finance 2017 126 M
Yield 2017 -
Sales 2018 0,01 M
EBIT 2018 -79,8 M
Net income 2018 -79,5 M
Finance 2018 98,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 27 482x
EV / Sales2018 31 425x
Capitalization 319 M
More Financials
Company
ObsEva SA provides therapeutic treatments to increase women's reproductivity.It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth.The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva,... 
More about the company
Surperformance© ratings of Obseva SA
Trading Rating : Investor Rating :
More Ratings
Latest news on OBSEVA SA
05/18 ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with..
05/11 ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Ca..
03/07 OBSEVA : Starts Phase 3 Clinical Program for Nolasiban in ART
More news
Sector news : Bio Therapeutic Drugs
09:50a U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/14 ObsEva beats by $0.03
10/12 YOUR DAILY PHARMA SCOOP : AcelRx DSUVIA PDUFA, Ardelyx Phase 3 Success, Rhopress..
10/11 Premarket analyst action - healthcare
10/10 ObsEva secures $60M private capital raise; shares up 11%
10/09 BIOTECH FORUM DAILY DIGEST : Where Does Flexion Therapeutics Go From Here?
Chart OBSEVA SA
Duration : Period :
Obseva SA Technical Analysis Chart | OBSV | CH0346177709 | 4-Traders
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 20,2 $
Spread / Average Target 88%
EPS Revisions
Managers
NameTitle
Ernest Loumaye Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Timothy M. Adams Chief Financial Officer
Jean-Pierre Gotteland Chief Scientific Officer
Elke Bestel Chief Medical Officer & Head-Pharmacovigilance
Sector and Competitors
1st jan.Capitalization (M$)
OBSEVA SA0.00%319
GILEAD SCIENCES1.16%94 693
REGENERON PHARMACEUTICALS6.67%41 304
VERTEX PHARMACEUTICALS100.10%36 699
GENMAB4.43%11 899
EXELIXIS, INC.76.93%7 707